Google
AMLX — AMYLYX PHARMACEUTICALS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
AMLX FAQ
What is AMLX's ROE?
AMYLYX PHARMACEUTICALS INC reports a Return on Equity (ROE) of -54.95%.
What is AMLX's dividend yield?
AMYLYX PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is AMLX's Quality Score?
Our AI rates AMLX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AMLX?
Our AI Timing Score for AMLX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AMLX belong to?
AMYLYX PHARMACEUTICALS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange
AMLX AI Analysis Summary
Our AI summary for AMLX: AMYLYX PHARMACEUTICALS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of -54.95%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 20.31
Price
-0.44
(-2.12%)
Day Change
|
|
|---|
AMLX, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 20.31 |
| PBV / Sector |
8.45 / 3.22
|
| Earning Per Share | -1.32 |
| PE / Sector |
N/A / 29.79
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
31.98 M
GREAT
|
| Average 1W Daily Value |
53.72 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:28 |
| Symbol | AMLX |
| Name | AMYLYX PHARMACEUTICALS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 111.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,307.12 / 10,754.62 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 55 Cambridge Parkway, Cambridge, MA, United States, 02142
Phone: 617 682 0917
Website: https://amylyx.com
Employees: 136
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
